Journal
NPJ GENOMIC MEDICINE
Volume 7, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41525-022-00316-x
Keywords
-
Categories
Funding
- University of Zurich
- Swiss National Science Foundation [320030_179547]
- Swiss National Science Foundation (SNF) [320030_179547] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
This study investigated the potential of preconception expanded carrier screening (ECS) to reduce the risk of neurodevelopmental disorders (NDDs). The results showed that the risk reduction potential was up to 43.5% for consanguineous couples and 5.1% for nonconsanguineous couples. However, the study found that underestimation of pathogenicity and other factors compromised the risk reduction potential. Therefore, it is recommended to screen for genetic mutations in all couples seeking ECS and set sensible pathogenicity thresholds to optimize clinical outcomes.
The magnitude of clinical utility of preconception expanded carrier screening (ECS) concerning its potential to reduce the risk of affected offspring is unknown. Since neurodevelopmental disorders (NDDs) in their offspring is a major concern of parents-to-be, we addressed the question of residual risk by assessing the risk-reduction potential for NDDs in a retrospective study investigating ECS with different criteria for gene selection and definition of pathogenicity. We used exome sequencing data from 700 parents of children with NDDs and blindly screened for carrier-alleles in up to 3046 recessive/X-linked genes. Depending on variant pathogenicity thresholds and gene content, NDD-risk-reduction potential was up to 43.5% in consanguineous, and 5.1% in nonconsanguineous couples. The risk-reduction-potential was compromised by underestimation of pathogenicity of missense variants (false-negative-rate 4.6%), inherited copy-number variants and compound heterozygosity of one inherited and one de novo variant (0.9% each). Adherence to the ACMG recommendations of restricting ECS to high-frequency genes in nonconsanguineous couples would more than halve the detectable inherited NDD-risk. Thus, for optimized clinical utility of ECS, screening in recessive/X-linked genes regardless of their frequency (ACMG Tier-4) and sensible pathogenicity thresholds should be considered for all couples seeking ECS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available